Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia

David C Linch; Robert K Hills; Alan K Burnett; Nigel Russell; Rosemary E Gale

doi:10.1111/bjh.17981

Therapy for isocitrate dehydrogenase 2 (IDH2)^R172 -mutant acute myeloid leukaemia

Br J Haematol. 2022 Mar;196(6):1348-1352. doi: 10.1111/bjh.17981. Epub 2021 Dec 6.

Authors

David C Linch¹, Robert K Hills², Alan K Burnett³, Nigel Russell⁴, Rosemary E Gale¹

Affiliations

¹ Department of Haematology, University College London (UCL) Cancer Institute, London, UK.
² Nuffield Department of Population Health, University of Oxford, Oxford, UK.
³ Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
⁴ Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham, UK.

PMID: 34870324
DOI: 10.1111/bjh.17981

Abstract

Although we earlier reported a very poor outcome for younger adult patients with isocitrate dehydrogenase 2 (IDH2)^R172 -mutated acute myeloid leukaemia (AML) entered into UK trials compared to IDH2^WT and IDH2^R140 -mutated patients, this was not corroborated by a study from the German-Austrian AML Study Group. We have therefore investigated a later cohort of IDH2-mutated patients to identify any changes in outcome and whether this could inform the optimal treatment for IDH2^R172 AML. We found an improved outcome for IDH2^R172 -mutated AML in the later trials and the data suggests that this may be due to the increased use of allogeneic transplantation to consolidate first remission.

Keywords: acute myeloid leukaemia; allogeneic transplantation; isocitrate dehydrogenase 2 (IDH2)R172 mutations; optimal therapy; prognostic impact.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Cohort Studies
Humans
Isocitrate Dehydrogenase* / genetics
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / therapy
Mutation
Prognosis

Substances

Isocitrate Dehydrogenase

Abstract

Publication types

MeSH terms

Substances

Grants and funding